


Getting started with Cortellis Digital Health Intelligence

What is Cortellis Digital Health Intelligence?

Cortellis Digital Health Intelligence is a single source of global data coverage and analysis of the digital health ecosystem. It allows you to track activities of innovators and competitors, choose ideal partners based on digital innovation potential and therapy area focus, and more. You can navigate the dynamic digital health landscape with a range of content including digital health companies, deals, clinical trials, patents, and press releases.

Search – Press Releases


The press release search will be for diabetes mellitus. On the home page, expand the Digital Health Intelligence area and click on View All Digital Health Press Releases.



The screenshot shows the Cortellis Digital Health Intelligence homepage. At the top, there is a search bar with a dropdown menu set to 'All' and a search button. Below the search bar, there are links for 'Advanced search', 'Structure search', and 'Search history'. The main content area is titled 'Digital Health Intelligence' and features two large cards: 'Digital Health Companies' and 'Digital Health Deals'. The 'Digital Health Companies' card includes a description: 'View profiles of digital health players and their R&D and commercialization activities to map the ecosystem and track innovators, competitors and potential partners'. The 'Digital Health Deals' card includes a description: 'View digital health deals and collaborations to inform partnering strategies and generate maximum return on your assets.' On the left side of the 'Digital Health Companies' card, there is a 'View All' section with three buttons: 'Digital Health Patents', 'Digital Health Press Releases' (which is highlighted with a red border), and 'Digital Health Trials'.


Results page and filters

A list of curated digital health press releases is displayed in chronological order, with the title, source, publication date and opening text for each one. Filters are listed on the left side of the page and can be used to refine the results. Click **Show all filters** to see a list of all filters on a new screen.




The screenshot shows the search results page for '6412 Digital Health Press Releases results'. The page includes a navigation bar with '< Back', 'Forward >', 'Search Results', 'Save and Alert', and 'Download'. Below the navigation bar, there are tabs for 'First', 'Previous', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'Next', and 'Last'. The 'Report Type' is set to 'Results', 'Per page' is 50, and 'Sort by' is 'Publication Date' (Most Recent). The 'Show selected only' button is checked. The 'Press Releases (6412)' filter is selected. The 'Refine Search' section shows a search within results box. The 'Primary Companies' filter is expanded, showing a list of companies: Medidata Solutions Worldwide (107), Cerner Corporation (70), and American Well Inc (53). The 'Show all filters' button is highlighted. The main content area displays a list of press releases, including 'MDCClone Expands to Canada', 'MDCClone Expands to Canada - Collaborating with The Ottawa Hospital, One of Canada's Largest Learning and Research Hospitals, to Democratize Health Data', 'AI-driven system that speeds up temperature screening piloted at 2 locations', and 'Atrius Health Engages Kyruus to Advance Novel Digital Patient Access Initiatives'.

Select the **Indications** filter and use the **Hierarchical List** to easily include sub-terms. Enter diabetes mellitus and click **Look up** to locate the term in the hierarchy. Diabetes mellitus and its sub-terms are automatically selected. To identify top companies in this space, select the **Primary Companies** filter next. Companies are listed by the number of press releases, in descending order. Select the first five and click **Apply**.



The screenshot shows the 'SHOW ALL FILTERS' dialog box. The 'Indications' filter is selected, and the 'Hierarchical List' is chosen. The search term 'diabetes mellitus' is entered, and the 'Look up' button is clicked. The resulting hierarchy shows 'Diabetes mellitus (288)' selected, along with its sub-terms: 'Non-Insulin dependent diabetes (79)', 'Insulin dependent diabetes (16)', and 'Gestational diabetes (8)'. The 'Primary Companies' filter is also selected, and the 'Frequency' view is chosen. The list of companies is shown, with the first five selected: Glooko Inc (15), Dariohealth Corp (12), Dexcom Inc (12), Livongo Health Inc (12), and Medtronic plc (12). The 'Apply' button is highlighted.

A company report is displayed. This provides a central hub to link to related content including press releases, deals, clinical trials, and patents. Non-digital-health related content may also be accessible depending on your Cortellis subscription.

Dexcom Inc		
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >	
Latest Press Releases	SNAPSHOT	
Latest Event Transcripts	Company Name	Dexcom Inc
Broker Research Reports	Parent Company Name	Dexcom Inc
Company Profile	Organization Type	Organization Sub-Type : Company Company Type : Public Company Size : Medium
Financials	Field of Activity	Software & Analytics ; Digital Health Device
Company Contacts	Private Equity Backed Status	Formerly PE/VC Backed
Subsidiary Companies	Website	http://www.dexcom.com/ 
Drug Sales and Forecasts	Country/Territory	US
Drugs	Number of Drugs In Active Development	0
Deals	Number of Inactive Drugs	0
Clinical Trials	Number of Patents as Owner	115
Patents	Number of Patents as Third Party	1
Change History	Number of Deals	14
Sources	Key Indications	Diabetes mellitus ; Heart disease ; Hypertension ; Hypotension ; Insulin dependent diabetes ; Respiratory disease ; Cholesterol metabolism disorder ; Non-Insulin dependent diabetes

Click the **Deals** tab to view deals related to the company. Deals are listed by type. To see a table of all the deals, click **View deals as a results list**.

Dexcom Inc		
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >	
Latest Press Releases	DEALS	
Latest Event Transcripts	Agreement Type	Target (Principal Company) Active Inactive Acquirer (Partner Company) Active Inactive Total
Broker Research Reports	Technology - Other Proprietary	5 0 7 0 12
Company Profile	Drug - Development/Commercialization License	0 0 1 0 1
Financials	Company - M&A (in whole or part)	0 1 0 1 1
Company Contacts	View deals as a results list	
Subsidiary Companies		
Drug Sales and Forecasts		
Drugs	Deal Asset Type	Principal Active Inactive Partner Active Inactive Total
Deals	+ Product	6 0 8 0 14
Agreement Type	+ Service	1 0 4 0 5
Asset & Transaction Type	+ Technology	2 0 2 0 4
Clinical Trials	+ Company/Business Unit	0 1 0 1 1
Patents	View deals as a results list	
Change History		
Sources		

The results list from the deals module is displayed, including deal title, principal/partner companies and deal types. Click a hyperlinked deal title to open a report.


14 deal results are associated with the 'Dexcom Inc' company report						
Report Type	Results	Per page: 50	Sort by: Most Recent Event Date	Order Columns	Financial Summary Download	View
Show selected only	✓ Deal Title	Principal Company	Partner Company	Agreement Type	Deal Asset Type	Deal Transaction Type
Deals (14)	✓ Livongo to integrate Dexcom's G6 Continuous Glucose Monitoring System into its platform to enhance clinical outcomes for diabetes patients	Dexcom Inc (Other (non industrial))	Livongo Health Inc (Other (non industrial))	Filters : [0] Technology - Other Proprietary	Filters : [0] Other Product Type ; Diagnostic ; Other Services	Filters : [0] Service Agreement
Refine Search		Other Company Names: Dexcom	Other Company Names: Eoshealth Inc; Livongo; Livongo Health Inc			
Search within Results	✓ Dexcom to combine CGM into Lilly's Connected Diabetes Ecosystem	Dexcom Inc (Other (non industrial))	Eli Lilly & Co (Pharma)	Technology - Other Proprietary	Other Technology	Collaboration (Shared responsibilities)
		Other Company Names: Dexcom	Other Company Names: Eli Lilly & Company; Eli Lilly and Company; Eli Lilly & Co; Eli			
▼ Deal Type	✓ Walgreens to add Dexcom to its health services connection tool	Walgreens Boots Alliance Inc (Other (non industrial))	Dexcom Inc (Other (non industrial))	Technology - Other Proprietary	Other Research Services ; Other Product Type	Service Agreement
▼ Agreement Type		Other Company Names: CR Walgreen and Co; Walgreen Co; Walgreen Co Deerfield Il;	Other Company Names: Dexcom			
<input type="checkbox"/> Technology - Other Proprietary (12)						
<input type="checkbox"/> Company - M&A (In whole or part) (1)						
<input type="checkbox"/> Drug - Development/Commercialization... (1)						
Show all filters						

The report includes key information on the deal, as well as a summary of deal events, financials and more.

DexCom and Verily to develop CGM devices against type II diabetes		
Snapshot	Highlight	<input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Drugs	SNAPSHOT	
Patents	Deal Title	DexCom and Verily to develop CGM devices against type II diabetes
Contract	Principal Company	Verily Life Sciences LLC (US) (Other (non industrial))
Events	Other Company Names (Principal Company)	
Financial	Partner Company	Dexcom Inc (US) (Other (non industrial))
Venture Funding	Other Company Names (Partner Company)	Dexcom
Mergers & Acquisition	Agreement Type	Technology - Other Proprietary
Sources	Deal Asset Type	Device; Product(s) only
Similar Deals	Deal Transaction Type	Collaboration (Shared responsibilities)
	Deal Status	Active
	Territories	
	Total projected value (Current-USD M)	605.00

Search – Deals

The deals search will be for major depressive disorder. On the home page, expand the Digital Health Intelligence area and click on **Digital Health Deals**.

**Cortellis™**

Explore ▾

en

All ▾

Search Cortellis

Index 🔍


Full Text 🔍

Advanced search | Structure search | Search history

Digital Health Intelligence


Digital Health Companies

View profiles of digital health players and their R&D and commercialization activities to map the ecosystem and track innovators, competitors and potential partners



Digital Health Deals

View digital health deals and collaborations to inform partnering strategies and generate maximum return on your assets.



View All

Digital Health Patents

Digital Health Press Releases

Digital Health Trials

Results page and filters

A list of curated digital health deals is displayed, with the title, principal/partner companies and deal types for each one. Filters are listed on the left side of the page and can be used to refine the results. Click **Show all filters** to see a list of all filters on a new screen.

[< Back](#)
[Forward >](#)

[Related Content](#)
[Save and Alert](#)
[Download](#)

4031 Digital Health results

First

Previous

1

2

3

4

5

6

7

8

9

10

Next

Last

Report Type

Show selected only

Deals (4031)

Refine Search

Search within Results

Search

▼ Deal Type

▼ Agreement Type

☐ Technology - Other Proprietary (3159)
 ☐ Company - M&A (in whole or part) (526)
 ☐ Drug - Funding (194)

Show all filters

Results

Per page: 50

Sort by: Most Recent Event Date

Oldest


Order Columns

Financial Summary Download

View

Deal Title	Principal Company	Partner Company	Agreement Type	Deal Asset Type	Deal Transaction Type
<div>✓</div> <div> Premier Health Group acquires Cloud Practice </div>	Cloud Practice Inc (Other (non industrial))	Premier Health Group Inc (Other (non industrial)) Other Company Names: Premier Health Services Inc; Proelium MMA Acquisition	Filters : [0] Company - M&A (in whole or part)	Filters : [0] Company	Filters : [0] Acquisition - Full (100%)
<div>✓</div> <div> DarioHealth and Albertsons to offer digital therapeutics solution for chronic diseases such as diabetes and hypertension </div>	Dariohealth Corp (Other (non industrial)) Other Company Names: LabStyle	Albertsons Companies Inc (Other (non industrial))	Technology - Other Proprietary	Other Product Type ; Other Services	Service Agreement
<div>✓</div> <div> BurnAlong to offer access to its online video classes and social support platform to Peerfit members </div>	BurnAlong (Other (non industrial))	Peerfit Inc (Other (non industrial))	Technology - Other Proprietary	Other Services ; Other Product Type	Service Agreement

Scroll down and select the **Indications** filter and use the **Hierarchical List** to easily include sub-terms. Enter major depressive disorder and click **Look up** to locate and automatically select it. Select the **Deal Transaction Type** filter, use the **Hierarchical List** and select Collaboration (Shared responsibilities). Select the **Technologies** filter and select Digital health software deal and Digital health device deal. Click **Apply**.



The image shows three overlapping screenshots of the Clarivate filters interface, illustrating the steps to apply specific filters:

- Top Screenshot (Indications Filter):** The "Indications" filter is selected. The "Look up" button is used to search for "major depressive disorder". The "Hierarchical List" is selected, and "Major depressive disorder (6)" is checked under the "Depression (52)" category.
- Middle Screenshot (Deal Transaction Type Filter):** The "Deal Transaction Type" filter is selected. The "Hierarchical List" is selected, and "Collaboration (Shared responsibilities) (3)" is checked under the "License (3)" category.
- Bottom Screenshot (Technologies Filter):** The "Technologies" filter is selected. The "Look up" button is used to search for "Digital health software deal" and "Digital health device deal". The "Frequency" filter view is selected, and both "Digital health software deal (3)" and "Digital health device deal (2)" are checked.

The "Apply" button is highlighted in the bottom right corner of the bottom screenshot.

A new results page is displayed. You can download information to share it with colleagues or set up an email alert to automatically be notified of new deals for this search. Click a hyperlinked deal title to open a report.

< Back

Forward >

Search Results

Related Content

Save and Alert

Download

3 Digital Health results with filter(s) applied: Collaboration (Shared responsibilities); Major depressive disorder; Digital health device deal; Digital health software deal

First

Previous

1

Next

Last

Report Type

Show selected only

Deals (4031)

Refine Search

Clear All

Search within Results

Search

Deal Type

Agreement Type

Technology - Other Proprietary (3)

Show all filters

Deal Asset Type

Deal Transaction Type

Results

Per page: 50

Sort by: Most Recent Event Date

Most Recent

Order Columns

Financial Summary Download

View

Deal Title

Pharmaceutical products incorporating Proteus's sensor-based technologies for two undisclosed therapeutic areas

Genomind to use Drchrono's platform to order assays for mental health

Otsuka and Click Therapeutics to develop and commercialize digital therapeutic, CT-152 for major depressive disorder worldwide

Principal Company

Proteus Digital Health Inc (Other (non industrial))

Other Company Names: Proteus Biomedical Inc; Vivomems Inc

Drchrono Inc (Other (non industrial))

Click Therapeutics Inc (Other (non industrial))

Partner Company

Otsuka Pharmaceutical Co Ltd (Pharma)

Other Company Names: Otsuka Pharma Co Ltd; Otsuka Pharmaceutical; Otsuka

Genomind Inc (Other (non industrial))

Otsuka America Pharmaceutical Inc (Pharma)

Other Company Names: Meretek Diagnostics Group of Otsuka America

Agreement Type

Filters : [0]

Technology - Other Proprietary

Technology - Other Proprietary

Technology - Other Proprietary

Deal Asset Type

Filters : [0]

Other Technology

Product(s) only ; Other Product Type

Product(s) only ; Device

Deal Transaction Type

Filters : [1]

Collaboration (Shared responsibilities)

Collaboration (Shared responsibilities)

Collaboration (Shared responsibilities)

Reports

The Events tab provides the original deal terms and updates to the deal over time.

Otsuka and Click Therapeutics to develop and commercialize digital therapeutic, CT-152 for major depressive disorder worldwide							
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >						
Drugs	EVENTS						
Patents	SUMMARY						
Contract	In January 2019, Otsuka America and Click Therapeutics entered into a collaboration agreement to develop and commercialize digital therapeutic, CT-152 for major depressive disorder worldwide [2108056] .						
Events	TIMELINE						
Summary							
Timeline							
Financial							
Venture Funding							
Mergers & Acquisition							
Sources							
Similar Deals	New						
Date	Event Type	Description	Drug(s)	Stage	Payment Type	Value (USD m)	
03-Jan-2019	Original Deal	<p>- In January 2019, Otsuka America and Click Therapeutics entered into a collaboration agreement to develop and commercialize digital therapeutic, CT-152 for major depressive disorder.</p> <p>- CT-152 is a mobile application (app).</p> <p>- CT-152 would use evidence-based cognitive therapy principles and Click's patient engagement platform to treat patients either independently or in combination with prescribed pharmacotherapies.</p> <p>- The aim of the collaboration is that the app would be classified as Software as a Medical Device (SaMD) and would fall under the FDA regulatory framework that supports innovation and commercialization of digital tools while protecting patient health.</p> <p>- Click would discover and validate a software application and organize it commercially, whereas Otsuka would use its expertise in development and commercialization of approved prescription therapies for patients with serious mental illnesses.</p> <p>- Otsuka would pay up to \$10 million in upfront and regulatory milestone payments, an estimated \$20 million in development funding, \$272 million in commercial milestone payments are contingent upon regulatory approvals plus tiered, double-digit royalties on worldwide sales of the software and the digital therapeutic applications [2108056].</p>			Upfront Payment to Principal Company;	Payment Unspecified	

The Financial tab provides the total deal size and a breakout of payment types, such as milestones and R&D funding.

Otsuka and Click Therapeutics to develop and commercialize digital therapeutic, CT-152 for major depressive disorder worldwide

Snapshot

Drugs

Patents

Contract

Events

Financial

Total Summary

Principal

Projected Current

Projected At-Signing

Paid

Partner

Projected Current

Projected At-Signing

Paid

Venture Funding

Mergers & Acquisition

Highlight ☐ Search Terms & Synonyms < Previous Next >

FINANCIAL

TOTAL SUMMARY (USD Millions)

Projected Current	Projected At-Signing	Paid
302.00	302.00	Payment Unspecified


PRINCIPAL

Projected Current

Payment Type	Value (USD Millions)	Notes
Milestones	+	272.00
R&D Funding	~ 20.00	An estimated \$20 million in development funding
Lump Sum	=< 10.00	Up to \$10 million in upfront and regulatory milestone payments.
Upfront Payment	Payment Unspecified	An estimated \$20 million in development funding
Payment Type	Value (%)	Notes
Royalty(%)	Payment Unspecified	Tiered, double-digit royalties on worldwide sales

Search – Companies

The company search will be for companies working in digital therapeutics and neurological disease. On the home page, expand the Digital Health Intelligence area and click on **Digital Health Companies**.



Results page and filters

A list of curated digital health companies is displayed, with the names, field of activity and other information. Filters are listed on the left side of the page and can be used to refine the results. Click **Show all filters** to see a list of all filters on a new screen.

< Back | Forward > Search Results Related Content Save and Alert Download

10484 Digital Health Companies results

First Previous 1 2 3 4 5 6 7 8 9 10 Next Last

Report Type	Results	Per page: 50	Sort by: Number of Drugs In Active Development	Highest to Lowest	Order Columns	View
Show selected only Companies (10484) Refine Search Search within Results <input type="text"/> <input type="button" value="Search"/>	<input checked="" type="checkbox"/> Company Name <input checked="" type="checkbox"/> Astellas Pharma Inc <input checked="" type="checkbox"/> Janssen Research & Development LLC <input checked="" type="checkbox"/> Dong-A ST Co Ltd	Filters : [0] Astellas Pharma Inc	Filters : [0] Organization Sub-Type : Company Company Type : Public Company Size : Large	Filters : [0] Consumer Health & Wellness ; Pharmaceuticals ; Biotechnology & Medical Research	Country/Territory Filters : [0] Japan	Key Indications Filters : [0] Cancer; Advanced solid tumor; Hypertension; Non-small-cell lung cancer; Hormone refractory prostate cancer; Squamous cell carcinoma; Pancreas tumor; Rheumatoid arthritis; Aspergillus infection; Breast tumor
			Organization Sub-Type : Company Company Type : Public Company Size : Small	Pharmaceuticals ; Microbiome Research ; Digital Health Analytics/Artificial Intelligence	US	Unidentified indication; Hormone refractory prostate cancer; Acute myelogenous leukemia; Cancer; Non-insulin dependent diabetes; Non-Hodgkin lymphoma; Advanced solid tumor; Alzheimers disease; Chronic lymphocytic
				Digital Imaging & Pathology ; Device & Implants ; Pharmaceuticals ; Biologics	South Korea	Unidentified indication; Cancer; Hypertension; Non-insulin dependent diabetes; Alzheimers disease; Rheumatoid arthritis; Ovary tumor; Anemia; Breast tumor; Gastritis; Hepatitis B virus infection; Neutropenia;

Parent Company Name

☐ Alphabet Inc (11)

☐ VitalHub Corp (11)


☐ WELL Health Technologies Corp (8)

[Show all filters](#)

Organization Sub-Type

Non Profit Type

Select the **Field of Activity** filter and use the **Hierarchical List** to easily select sub-terms. Expand Digital Health and select Digital Therapeutics. Select the **Key Indications** filter, use the **Hierarchical List** and select Neurological disease. Click **Apply**.



SHOW ALL FILTERS

Search Field of Activity Look up

☐ Non-Hierarchical List
☒ Hierarchical List

- Academic/Research (249)
- Biotechnology & Medical Research (438)
- Business Support Services (742)
- Clinical Trial Research (166)
- Consulting & Commercial Services (200)
- Contract Organization (91)
- Diagnostics & Testing (634)
- Digital Health (10484)
 - Connected Healthcare Platforms (1332)
 - Consumer Health & Wellness (867)
 - Digital Health Analytics/Artificial Intelligence (1882)
 - Digital Health Clinical Trial Research (320)
 - Digital Health Device (1032)
 - Digital Health Software (6318)
 - Digital Imaging & Pathology (654)
 - ☒ Digital Therapeutics (291)

Field of Activity

SHOW ALL FILTERS

Search Key Indications Look up

☐ Non-Hierarchical List
☒ Hierarchical List

- Andrology (1)
- Cardiovascular disease (31)
- Degeneration (3)
- Dermatological disease (5)
- Endocrine disease (23)
- Gastrointestinal disease (25)
- Genetic disorder (6)
- Genitourinary disease (8)
- Growth disorder (5)
- Gynecology and obstetrics (3)
- Hematological disease (5)
- Immune disorder (14)
- Infectious disease (14)
- Inflammatory disease (11)
- Injury (6)
- Metabolic disorder (26)
- Musculoskeletal disease (8)
- Neoplasm (17)
- ☒ Neurological disease (34)
- Nutritional disorder (7)
- Ocular disease (3)

Key Indications

Cancel Apply

A new results page is displayed. You can download information to share it with colleagues or set up an email alert to automatically be notified of new information related to these companies. Click a hyperlinked company name to open a report.

< Back Forward > Search Results [Related Content](#) [Save and Alert](#) [Download](#)

34 Digital Health Companies results with filter(s) applied: Digital Therapeutics; Neurological disease

First Previous 1 Next Last

Report Type	Results	Per page: 50	Sort by: Number of Drugs In Active Development	Highest to Lowest	Order Columns	View
Show selected only	<input checked="" type="checkbox"/> Company Name	Parent Company Name	Organization Type	Field of Activity	Country/Territory	Key Indications
Companies (10484)	Filters: [0]	Filters: [0]	Filters: [1] Clear	Filters: [0]	Filters: [1] Clear	
Refine Search Clear All	<input checked="" type="checkbox"/> Orexo AB	Orexo AB	Organization Sub-Type: Company Company Type: Public Company Size: Small	Digital Therapeutics; Pharmaceuticals; Digital Health Software	Sweden	Opiate dependence; Pain; Immediate type hypersensitivity; Anus pain; Cancer pain; Chemotherapy-induced emesis; Testosterone deficiency; Drug dependence; Allergy; Attention deficit hyperactivity disorder; Bipolar
Search within Results	Search					

Reports


A company report is displayed. This provides a central hub to link to related content including press releases, deals, clinical trials, and patents. Non-digital-health related content may also be accessible depending on your Cortellis subscription. Other information is also available in the report, such as a Company Profile.

Orexo AB	
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Latest Press Releases	SNAPSHOT
Latest Event Transcripts	Company Name Orexo AB
Broker Research Reports	Parent Company Name Orexo AB
Company Profile	Organization Type Organization Sub-Type : Company Company Type : Public Company Size : Small
Funding	Field of Activity Digital Health Software ; Pharmaceuticals ; Digital Therapeutics
Financials	Private Equity Backed Status
Company Contacts	Website https://orexo.se/
Subsidiary Companies	Country/Territory Sweden
Drug Sales and Forecasts	Number of Drugs In Active Development 11
Drugs	Number of Inactive Drugs 27
Deals	Number of Patents as Owner 126
Clinical Trials	Number of Patents as Third Party 12
Patents	Number of Deals 55
Change History	Key Indications Opiate dependence ; Pain ; Immediate type hypersensitivity ; Anus pain ; Cancer pain ; Chemotherapy-induced emesis ; Testosterone deficiency ; Drug dependence ; Allergy ; Attention deficit hyperactivity disorder ; Bipolar disorder ; Deep vein thrombosis ; Depression ; Migraine ; Obsessive compulsive disorder ; Schizophrenia
Sources	

Orexo AB	
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Latest Press Releases	COMPANY PROFILE
Latest Event Transcripts	SUMMARY
Broker Research Reports	Orexo AB operates is a pharmaceutical company. The Company develops improved drugs based on drug delivery technologies, as well as focuses on opioid addiction and pain.
Company Profile	ACQUISITIONS AND SPIN-OFFS
Funding	In April 2015, Orexo was to divest subsidiary Kibion to a team of Swedish investors [1655648].
Financials	In July 2011, Orexo, through its subsidiary Kibion, acquired Wagner Analysen Technik, a German manufacturer of IRIS instruments and substrates for diagnostic breath tests, for EUR 1.4 million (US \$1.96 million) [1207476].
Company Contacts	In February 2009, Orexo acquired PharmaKodex for a tranche of 843,992 Orexo shares and one of shares or cash, due in August 2009. The acquisition of PharmaKodex included five employees and the company had enough cash for operations into 2010 [985957].
Subsidiary Companies	In November 2007, Orexo acquired Biolipox [854156]. Earlier in November 2007, the companies reported a revision to the transaction structure for Orexo's planned acquisition of Biolipox. The acquisition would still be implemented through an issue to Biolipox' shareholders of 8.56 million Orexo shares. An additional deferred payment of 0.926 million would be available in the form of warrants entitling Biolipox to an equal number of shares in Orexo. The warrants would only be exercisable if an out-licensing agreement was established for either Biolipox's NLA (for rhinitis), BLX-CLI or BLX-Eoxin, or if a milestone payment was received for the MPI project (for inflammatory pain). If none of these events were to occur by the end of December 2009, the warrants would be forfeited [850603]. In October 2007, Orexo agreed to acquire Biolipox. The transaction valued the offer for Biolipox at SEK 856 million (approximately \$132 million), which would be made in the form of 8.56 million Orexo shares. Upon approval and completion of the transaction, anticipated sometime in November, Biolipox shareholders would own approximately 38% of the combined company, which would retain the Orexo name. The acquisition was expected to be completed at the end of November 2007, with a meeting to seek Orexo shareholder approval set for November 13, 2007 [839191], [844522], [845158].
Drug Sales and Forecasts	In August 2004, Orexo acquired CePeP AB, the developer of a technology based on the concept of cell-penetrating peptides [555372].
Drugs	FINANCIAL
Deals	In February 2021, Orexo AB issued senior unsecured callable floating rate bonds in the amount of SEK 500 million, under a framework of SEK 1,000 million with final maturity in February 2025 [2402542].
Clinical Trials	In June 2019, the company resolved to issue and immediately thereafter repurchase 325,000 class C shares. Danske Bank subscribed for the entire issue of new class C shares at a subscription price of SEK 0.40 (US \$0.044) per share, equal to the quota value of the shares. The entire issue of class C shares would thereafter be repurchased by Orexo for SEK 0.40 (US \$0.044) per share. The class C shares do not entitle to dividends [2132047], [2161853]. In February 2020, the company board had resolved to initiate a repurchase program of ordinary shares, a maximum of 500,000 shares [2245426]. In March 2020, the company repurchased 14% of its outstanding unsecured corporate bonds with a
Patents	
Change History	
Sources	

Search – Patents


The patent search will be for patents related to major depressive disorder. On the home page, expand the Digital Health Intelligence area and click on View All **Digital Health Patents**.



The screenshot shows the Cortellis homepage. At the top, there is a search bar with the text "Search Cortellis" and buttons for "Index" and "Full Text". Below the search bar, there are links for "Advanced search", "Structure search", and "Search history". The main content area is titled "Digital Health Intelligence" and features two large cards: "Digital Health Companies" and "Digital Health Deals". To the left of these cards, there is a "View All" section with a button for "Digital Health Patents" highlighted by a red box. Other buttons in this section include "Digital Health Press Releases" and "Digital Health Trials".

Results page and filters

A list of curated digital health patents is displayed, with titles, owner companies and other information. This default display is the Abstract View. Other views can be accessed using the View buttons in the upper right. For example, clicking the pie chart button will create a visualization for additional insights. NOTE: different views are available for clinical trials and deals as well. Filters are listed on the left side of the page and can be used to refine the results. Click **Show all filters** to see a list of all filters on a new screen.



The screenshot shows the search results page for "33525 Digital Health Patent results". The page includes a navigation bar with "Back", "Forward", and "Search Results" buttons. On the right, there are buttons for "Analyze", "Save and Alert", and "Download". The main content area displays a list of patents, with the first two results highlighted by red boxes. The first result is "EP-01284121" with the title "Physiological sample collection devices and methods of using the same" and owner "LifeScan Inc". The second result is "EP-01462053" with the title "An improved lance with two elements" and owner "LifeScan Inc". On the left side, there is a "Refine Search" section with a "Search within Results" input field and a "Search" button. Below this, there is a "Owner Companies" filter section with a red box highlighting the "Show all filters" button. The filter section lists "Individual (2421)", "Citizen Holdings Co Ltd (1153)", and "Citizen Watch Co Ltd (743)". At the bottom, there is a "Third Party Companies" section with a red box highlighting the "Show all filters" button. The filter section lists "Blood Separation And Analyte Detection Techniques" and "LifeScan Inc".

Select the **Indications** filter and use the **Hierarchical List** to easily include sub-terms. Enter major depressive disorder and click **Look up** to locate the term in the hierarchy. Major depressive disorder is automatically selected. Click **Apply**.

SHOW ALL FILTERS

☐ Non-Hierarchical List
☒ Hierarchical List

Company Relationships
Drugs
Drug Relationships
Indications
Target-based Actions
Technologies
Patent Type
Abstract Classification
Patent Authority
Publication Date
Priority Date
Added Date
First Publication Date
Last Change Date
Term Adjusted

- ☐ Injury (620)
- ☐ Metabolic disorder (2404)
- ☐ Mouth disease (110)
- ☐ Musculoskeletal disease (613)
- ☐ Neoplasm (1669)
- ☐ Neurological disease (2755)
- ☐ Nutritional disorder (178)
- ☐ Ocular disease (572)
- ☐ Otorhinolaryngological disease (179)
- ☐ Prophylaxis (8)
- ☒ **Psychiatric disorder (916)**
 - ☐ Anxiety disorder (273)
 - ☐ Drug dependence (233)
 - ☐ Eating disorder (8)
 - ☐ Factitious disorder (1)
 - ☐ Impulse control disorder (1)
 - ☒ **Mood disorder (212)**
 - ☒ **Depression (182)**
 - ☒ **Major depressive disorder (21)**
 - ☐ Melancholia (1)
 - ☐ Postnatal depression (2)
 - ☐ Seasonal affective disorder (3)

A new results page is displayed. This can include an annotation highlighting the commercial significance of the invention. You can download information to share it with colleagues or set up an email alert to automatically be notified of new patents for this search. Click on a hyperlinked patent number to open a patent report.

< Back
Forward >
Search Results
Analyze
Save and Alert
Download

21 Digital Health Patent results with filter(s) applied: Major depressive disorder
First
Previous
1
Next
Last

Report Type
Results
Per page: 50
Sort by: Last Change Date
Most Recent
Order Columns
View
Expand all

Show selected only
☒

Patents (33525)
☒
WO-2021195784

Refine Search

Search within Results

Enhanced Title	Method for treating patient suffering from e.g. mental disorder, involves receiving prototype corresponding to patient from machine learning algorithm, and generating interface based on predicted efficacy of treatments and prototype
Title	Systems and methods for treatment selection
Abstract Classification	Central and Peripheral Nervous Systems

☒
WO-2022177728

Enhanced Title	Machine-learning based system for identifying and monitoring e.g. bipolar disorder, has processors outputting mental health disorders-based decision by inputting received physiological data into inference model
Title	System and method for mental health disorder detection system based on wearable sensors and artificial neural networks
Abstract Classification	Central and Peripheral Nervous Systems
Owner Companies	Princeton University
Novelty	The system has processors interacting with a set of wearable medical sensors (WMSs). The processors receive physiological data from the WMSs, train a neural network based on raw physiological data augmented with synthetic data and subjected to a grow-and-prune paradigm i.e. iterative, to generate a mental health disorder inference model, and output a mental health disorder-based decision by inputting the received physiological data into the generated mental health disorders inference model. The physiological data comprises one of galvanic skin response, skin temperature, inter-beat interval, and three-way acceleration received from a smartwatch. The processors output mental health disorders-based decision by inputting the received physiological data into an inference model. Machine-learning based system for identifying and monitoring mental health disorder e.g. schizoaffective disorder, major depressive disorder and bipolar disorder.
Annotation	Machine-learning based system for identification and monitoring of mental health disorder such as schizoaffective disorder, major depressive disorder, and bipolar disorder. The system comprises wearable electroencephalogram sensors, and processors. See

Reports


A patent report is displayed. The Snapshot includes the title, inventor abstract, patent type and other information. The Editorial Abstract includes additional detail, such as the novelty of the invention.

WO-2022177728	
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Companies and Drugs	SNAPSHOT
Editorial Abstract	Patent Number WO-2022177728
Chemical Structures	Title System and method for mental health disorder detection system based on wearable sensors and artificial neural networks
Claims	Original Assignee The Trustees Of Princeton University
Documents and Status	Inventor Abstract According to various embodiments, a machine-learning based system for mental health disorder identification and monitoring is disclosed. The system includes one or more processors configured to interact with a plurality of wearable medical sensors (WMSs). The processors are configured to receive physiological data from the WMSs. The processors are further configured to train at least one neural network based on raw physiological data augmented with synthetic data and subjected to a grow-and-prune paradigm to generate at least one mental health disorder inference model. The processors are also configured to output a mental health disorder-based decision by inputting the received physiological data into the generated mental health disorder inference model.
Expiry	Patent Type Diagnostic, Analysis and Assay; Digital Health
	Indications Schizoaffective disorder; Major depressive disorder; Bipolar disorder
	Target-based Actions
	Other Actions CNS diagnostic agent
	Technologies EEG; Analytical method
	Inventors Zhang, Zhao; Yin, Hongxu; Hassantabar, Shayan; Jha, Niraj, K.
	IPC Codes G06N 3/08; G06F 17/18; A61B 5/00; A61B 5/0205; G16H 50/20; A61B 5/02
	Manual Codes
	First Estimated Expiry in Family
	First Publication in Family 25-Aug-2022 WO-2022177728-A1
	Most Recent Publication in Family 25-Aug-2022 WO-2022177728-A1

WO-2022177728	
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Companies and Drugs	EDITORIAL ABSTRACT
Editorial Abstract	Summary Abstract
Summary Abstract	Document Written From WO-2022177728
DWPI Abstract	Enhanced Title Machine-learning based system for identifying and monitoring e.g, bipolar disorder, has processors outputting mental health disorders-based decision by inputting received physiological data into inference model
Chemical Structures	Abstract Classification Central and Peripheral Nervous Systems
Claims	Novelty The system has processors interacting with a set of wearable medical sensors (WMSs), The processors receive physiological data from the WMSs, train a neural network based on raw physiological data augmented with synthetic data and subjected to a grow-and-prune paradigm i.e, iterative, to generate a mental health disorder inference model, and output a mental health disorder-based decision by inputting the received physiological data into the generated mental health disorders inference model, The physiological data comprises one of galvanic skin response, skin temperature, inter-beat interval, and three-way acceleration received from a smartwatch, The processors output mental health disorders-based decision by inputting the received physiological data into an inference model, Machine-learning based system for identifying and monitoring mental health disorder e.g, schizoaffective disorder, major depressive disorder and bipolar disorder.
Documents and Status	Advantage The neural network is trained based on raw physiological data augmented with synthetic data and subjected to a grow-and-prune paradigm to generate at least one mental health disorder inference model, and thus enables to identify and monitor mental illnesses based on wearable medical sensor data and neural network processing that bypasses feature extraction and generates synthetic data.
Expiry	


Search – Trials

The trials search will be for trials related to major depressive disorder. On the home page, expand the Digital Health Intelligence area and click on View All **Digital Health Trials**.




Results page and filters

A list of curated digital health trials is displayed, with titles, conditions, biomarkers, and other information. Filters are listed on the left side of the page and can be used to refine the results. Click **Show all filters** to see a list of all filters on a new screen.



Title	Condition	Patient Segment	Biomarkers	Interventions	Phase
Clinical application of cricoid cartilage compression in patients with belching during gastroscopy	Dyspepsia; Gastroesophageal reflux		Heart rate ; Oxygen saturation	Cricoid cartilage compression alone; Clinical practice alone	Phase Not Applicable
Improving Mobility Via Robotic Exoskeletons in Local Rehabilitation Settings in Singapore	Movement disorder		Gait ; Six-minute walk distance	EksoGT exoskeleton alone; conventional physiotherapy alone; robotic exoskeleton-assisted gait training alone	Phase Not Applicable
Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia	Schizoaffective disorder; Schizophrenia			Variable regimens including Digital Health intervention Siemens 3T Prisma , Digital Health intervention Sonicator-1000 system , MRI , pulsed low-intensity focused ultrasound (PLIFUS)	Phase 2 Clinical

Select the **Condition** filter and use the **Hierarchical List** to easily include sub-terms. Enter major depressive disorder and click **Look up** to locate the term in the hierarchy. Major depressive disorder is automatically selected. Scroll down and select the Results Available filter. Check Yes and click **Apply**.



SHOW ALL FILTERS

major depressive disorder **Look up**

Condition

Non-Hierarchical List

Hierarchical List

Prophylaxis (41)

Psychiatric disorder (3019)

Adjustment disorder (3)

Anxiety disorder (1213)

Drug dependence (702)

Eating disorder (79)

Impulse control disorder (10)

Mood disorder (793)

Depression (726)

Major depressive disorder (136)

SHOW ALL FILTERS

Secondary Endpoints


Results Available

No (134)

Yes (2)

Cancel **Apply**

A new results page is displayed. You can download information to share it with colleagues or set up an email alert to automatically be notified of new/updated trials for this search. Click on a hyperlinked trial title to open a report.



< Back | Forward > Search Results Related Content Analyze Save and Alert Download

2 Digital Health Trials results with filter(s) applied: Major depressive disorder; Yes

Report Type	Results	Per page: 50	Sort by: Last Change Date	Most Recent	Order Columns	View
Clinical Trials (18511)	Title	Condition	Patient Segment	Biomarkers	Interventions	Phase
	Filters: [1] Clear	Filters: [0]	Filters: [0]	Filters: [0]	Filters: [0]	
	STARS-MDD: Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD	Cognitive disorder; Major depressive disorder	Depression - Subjects with Relapsed/Recurrent Disease; Depression - Subjects with specific disease - Subjects with Major Depressive Disorder		AKL-T09 alone; ALK-T03 alone; Videogame-like digital therapy alone; antidepressant medication alone	Phase not specified
	FLATTI: Adding smartphone cognitive-behavior therapy to pharmacotherapy for major depression: A randomized, control trial	Major depressive disorder	Depression - Subjects with specific disease - Subjects with Major Depressive Disorder		Kokoro-App smartphone cognitive-behavior therapy alone; escitalopram plus sertraline	Phase 2 Clinical

Condition

Filters[1] Clear

Major depressive disorder (2)

Show all filters

Patient Segment

Reports

A trial report is displayed. The Snapshot includes the title, primary interventions, recruitment status and other information. The Protocol & Results includes aims and scope of the trial, results, and adverse events. Other tabs include Subjects & Measurements and Registry Contacts & Sites.

Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD		
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >	
Protocol & Results	<div> <div>SNAPSHOT</div> <div> <div>Results Available</div> <div>Yes</div> <div>Endpoints Met</div> <div>Unspecified</div> </div> </div>	
Subjects & Measurements	Title	Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD
Registry Contacts & Sites	Scientific Title	A Randomized, Double-blind, Controlled, six-week Trial to Assess the Impact of Novel Digital Interventions Designed to Improve Cognitive Dysfunction as Adjunct Therapy to Antidepressant Medication in Adults With Major Depressive Disorder
Change History	Identifiers	NCT03310281; AKILI-035; STARS-MDD
Sources	Condition	Cognitive disorder; Major depressive disorder View Epidemiology in IPD
	Disease Markers	
	Primary Interventions	AKL-T09 alone ALK-T03 alone Videogame-like digital therapy alone antidepressant medication alone
	Active Controls	
	Phase	Phase not specified
	Recruitment Status	Completed
	Reason for Trial Discontinuation	
	Sites	4
	Sponsor Only	Akili Interactive Labs Inc

Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD		
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >	
Protocol & Results	<div> <div>PROTOCOL & RESULTS</div> <div> <div>AIMS & SCOPE</div> <div> <p>The purpose of this randomized, parallel-group, controlled, double-blind study was to evaluate the effects of videogame-like digital therapies as adjunct therapy to antidepressant medications on cognitive deficits associated with major depressive disorder [2650302].</p> </div> </div> </div>	
	<div> <div>PROTOCOL DESCRIPTION TEXT</div> <div> <p>This study would consist of three primary phases: pre-screening, baseline, and treatment. During the Pre-screening phase (Day -28 to Day 0), participants would undergo pre-screening to evaluate eligibility for the study. Pre-screening would take place up to 28 days before the Baseline Visit (Day 0). Pre-screening would take place either over the phone, or in the clinic. On Day 0, the Baseline visit would occur wherein additional eligibility criteria would be established. The Treatment phase (Day 1 to 42) would involve using the digital therapy at home for each participant followed by an In-Clinic assessment on Day 42 to assess key outcomes. During the Treatment phase patients would be instructed to play their videogame-like intervention for approximately 25 min per day for 5 days per week. Compliance with treatment/use requirements would be monitored remotely during this phase.</p> <p>This study consists of two experimental arms: Arm 1: patients would receive ALK-T03, a digital intervention that requires the patient to navigate a character through a game-like space, while collecting objects, in a fixed period of time. Arm 2: patients would receive AKL-T09, a digital intervention that requires the patient to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.</p> </div> </div>	
	<div> <div>PATIENTS WERE RANDOMIZED 1:1 TO AKL-T03 OR A DIGITAL CONTROL, BOTH OF WHICH WERE ADMINISTERED USING APPLE IPAD MINI 2 TABLETS. PATIENTS IN THE AKL-T03 ARM WERE INSTRUCTED TO COMPLETE FIVE SESSIONS, AT LEAST FIVE DAYS PER WEEK FOR SIX WEEKS, FOR A TOTAL OF APPROXIMATELY 25 MINUTES OF GAME-PLAY PER DAY. THE SOFTWARE AUTOMATICALLY LOCKED AFTER THE FIVE SESSIONS WERE COMPLETED, TO PRECLUDE EXCESSIVE USE OF THE INTERVENTION. PARTICIPANTS ASSIGNED TO THE CONTROL ARM ALSO WERE INSTRUCTED TO COMPLETE 25 MINUTES OF GAME-PLAY FOR AT LEAST FIVE DAYS PER WEEK FOR SIX WEEKS; THIS SOFTWARE ALSO AUTOMATICALLY LOCKED AFTER 25 MINUTES [2650434].</div> </div>	
	<div> <div>REGIMENS</div> <div> <p>Patients were randomized 1:1 to AKL-T03 or a digital control designed to have an equal expectation of benefit [2650434], [2650302], [2650961].</p> <p>Patients in the intervention group were trained by staff on how to use the video game therapy. Following the training, patients were instructed to complete five sessions, five days per week for six weeks. Meanwhile, control group patients were told to spend 25 min on game play at least five days a week for six weeks [2650961].</p> </div> </div>	
	<div> <div>RESULTS TEXT</div> <div> <p>In April 2022, results were presented. Addition of AKL-T03 to antidepressant therapy significantly improved sustained attention in adults diagnosed with MDD compared to the control (p = 0.005), as measured by the Test of Variables of Attention (TOVA), which was a computerized test to assess attention deficits and evaluate the effects of interventions in ADHD [2650434], [2650302].</p> <p>In April 2022, results were presented. There were no statistically significant difference in depression symptoms between patients in the control and intervention groups, though both groups did statistically improve from baseline. Treatment with AKL-T03 resulted in significant improvement in sustained attention, as well as in cognitive functioning as a whole compared to a control intervention [2650961].</p> </div> </div>	

For more information contact Customer Service at [LS Product Support](#).